These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25045058)

  • 1. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
    Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
    Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LA; Myers O; Cuzick J; Wentzensen N; Kinney W; Castle PE; Wheeler CM;
    Obstet Gynecol; 2016 Dec; 128(6):1248-1257. PubMed ID: 27824767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
    Wong AK; Chan RC; Nichols WS; Bose S
    Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
    Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
    Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
    J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical Squamous Cells of Undetermined Significance Cervical Cytology Report Rate and Histologic Follow-up Findings From the Largest College of American Pathologists-Certified Laboratory in China.
    Zheng B; Yang H; Li Z; You J; Wei G; Zhang H; Zeng Z; Xie F; Zhao C
    Arch Pathol Lab Med; 2019 Jun; 143(6):748-752. PubMed ID: 30605022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silent High Grade Cervical Intraepithelial Neoplasia in Atypical Smears from Liquid Based Cervical Cytology - Three Years Experience in Thammasat University Hospital.
    Lertvutivivat S; Chanthasenanont A; Chanthasenanont A; Muangto T; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
    Asian Pac J Cancer Prev; 2016; 17(9):4353-4356. PubMed ID: 27797243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.
    Castle PE; Kinney WK; Xue X; Cheung LC; Gage JC; Poitras NE; Lorey TS; Katki HA; Wentzensen N; Schiffman M
    J Natl Cancer Inst; 2019 Aug; 111(8):820-827. PubMed ID: 30576462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S50-5. PubMed ID: 23519305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
    Ryu KJ; Lee S; Min KJ; Kim JW; Hong JH; Song JY; Lee JK; Lee NW
    Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.